Previous Close | 5.33 |
Open | 5.33 |
Bid | 5.26 x 100 |
Ask | 5.36 x 200 |
Day's Range | 5.11 - 5.43 |
52 Week Range | 2.24 - 11.10 |
Volume | |
Avg. Volume | 92,107 |
Market Cap | 79.15M |
Beta (5Y Monthly) | 2.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.56 |
Earnings Date | May 21, 2024 - May 27, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.29 |
Subscribe to Yahoo Finance Plus to view Fair Value for AFMD
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.A
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be a
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.